SCHEDULE: CASI Pharma Secures $5M Convertible Note from ETP Global III

CASI Pharmaceuticals, Inc. announced ETP Global III Fund L.P. purchased a $5 million convertible note, marking the third tranche of a $20 million financing.

Summary

• ETP Global III Fund L.P. purchased a convertible note with a principal amount of US$5 million from CASI Pharmaceuticals, Inc. on February 19, 2026.
• This transaction represents the third tranche of the Issuer's US$20 million convertible note financing.
• The note bears a simple interest rate of 12% per annum, with interest payable on the first business day of each calendar quarter, commencing July 1, 2026.
• The maturity date for the convertible note is February 18, 2029.
• The holder (ETP Global III Fund L.P.) has the right to convert the outstanding principal and accrued interest into Ordinary Shares at any time from the 91st day after issuance until the maturity date.
• The conversion price will be the volume weighted average closing price of the Company's Ordinary Shares during the five consecutive trading days immediately preceding the conversion notice, with a floor of US$1.00 and a ceiling of US$2.00 per Ordinary Share.
• The Company also has the option to convert the note into Ordinary Shares at maturity.
• Wei-Wu He, Ph.D., reported beneficial ownership of 18,985,535 Ordinary Shares, representing 53.0% of the class, calculated based on 20,555,873 Ordinary Shares outstanding as of March 20, 2026.
• This beneficial ownership includes 15,000,000 shares issuable upon conversion of three convertible notes (including this one) within 60 days, assuming a US$1.00 conversion price, given the recent average volume-weighted closing price of US$0.15.
• The proceeds from this note are primarily designated for clinical trials in China for CID-103 to achieve value-creating milestones and for general company operations.
• The note is general unsecured debt and is subordinate to the Company's secured debt.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it secures necessary funding for clinical trials, but the high interest rate and potential dilution at a premium conversion price introduce some caution.

Positives

• Secured US$5 million in financing, contributing to a total of US$20 million, providing capital for operations and strategic initiatives.
• Funds are earmarked for clinical trials in China for CID-103, which aims to achieve value-creating milestones.
• The convertible nature of the debt offers flexibility, allowing the company to defer immediate equity dilution while securing necessary capital.

Negatives

• The convertible note carries a relatively high simple interest rate of 12% per annum, increasing debt servicing costs.
• The note is unsecured and subordinate to the company's secured debt, indicating a higher risk profile for the noteholder.
• The conversion price range of US$1.00 to US$2.00 is significantly higher than the recent average volume-weighted closing price of US$0.15, which could imply a substantial premium for conversion or a significant expectation of future share price appreciation.
• Restrictions on using proceeds for significant U.S. clinical trials without holder approval could limit the company's strategic flexibility in certain markets.

Risks

• Dilution Risk: Conversion of the note into ordinary shares could dilute existing shareholders, especially if the conversion occurs at the lower end of the conversion price range or if the market price remains low.
• Subordination Risk: The convertible note is general unsecured debt and subordinate to the company's secured debt, meaning noteholders would have lower priority in the event of liquidation.
• Default Risk: Failure by the company to repay the outstanding balance or interest, or other events like insolvency, could trigger an Event of Default, allowing the holder to demand immediate repayment.
• Conversion Price Volatility: The conversion price is tied to the volume-weighted average closing price, which can fluctuate, impacting the number of shares issued upon conversion.
• Operational Risk: The use of proceeds for clinical trials in China for CID-103 carries inherent risks associated with drug development, including trial success, regulatory approval, and market adoption.
• Strategic Flexibility Limitation: The restriction on using proceeds for significant U.S. clinical trials without holder approval could limit the company's ability to pursue certain strategic initiatives.

Future Outlook

The company intends to use the proceeds primarily for clinical trials in China for CID-103 to achieve value-creating milestones and for general operations. The convertible note provides a mechanism for future equity conversion by either the holder or the company, potentially increasing the number of outstanding shares.

Industry Context

StockSavvy.ai notes that securing additional convertible debt financing is a common strategy for biotechnology and pharmaceutical companies like CASI Pharmaceuticals, Inc., especially those focused on clinical-stage assets such as CID-103. This type of financing allows companies to fund research and development without immediate equity dilution, deferring it until conversion. The focus on clinical trials in China aligns with a broader trend of pharmaceutical companies expanding their R&D and market presence in the region.

Comparison to Industry Standards

• A 12% interest rate on a convertible note can be considered on the higher side for established pharmaceutical companies but may be typical for smaller, clinical-stage biotechs with higher perceived risk. For example, larger biopharma companies might secure convertible debt at 2-6% interest, while early-stage firms might see rates from 8-15% depending on market conditions and company specifics.
• The conversion price range of US$1.00 to US$2.00, significantly above the recent market price of US$0.15, suggests that the investors are betting on a substantial future increase in share value, which is common in high-risk, high-reward biotech investments. This contrasts with more mature companies where conversion prices are often set closer to the current market price with a modest premium.
• The subordination of the note to secured debt is standard practice for unsecured convertible debt in the industry, reflecting the typical capital structure hierarchy.

Related Party Transactions

• Wei-Wu He, Ph.D., is the founder and managing partner of Emerging Technology Partners, LLC (ETP), which is the general partner of ETP Global Fund L.P., ETP Global III Fund L.P., and ETP BioHealth III Fund, L.P. He is also a trustee of HE Family GRAT.
• Huiying Memorial Foundation, a 501(c)(3) private family foundation, is also a reporting person, and Wei-Wu He, Ph.D., is an officer and a board member, though he disclaims beneficial ownership of its shares.
• The purchase of the convertible note by ETP Global III Fund L.P. from CASI Pharmaceuticals, Inc. constitutes a related-party transaction given Wei-Wu He's multiple roles and significant beneficial ownership in CASI and the ETP entities.

Stakeholder Impact

• Shareholders: Potential for dilution upon conversion of the note, but also potential for value creation if clinical trials for CID-103 are successful. The high conversion price range suggests a belief in future share price appreciation.
• Creditors: The convertible note is unsecured and subordinate to secured debt, placing these noteholders at a lower priority than secured creditors.
• Employees: Continued funding for operations and clinical trials supports ongoing employment and R&D efforts.
• Customers (future): Successful clinical trials for CID-103 could lead to new product offerings.

Next Steps

• Continued clinical trials in China for CID-103.
• Interest payments on the convertible note, commencing July 1, 2026.
• Potential conversion of the note into ordinary shares by the holder or the company between the 91st day after issuance and the maturity date.
• Repayment of the outstanding balance and accrued interest on the Maturity Date (February 18, 2029) if not converted.

Key Dates

Recommendation

While the financing provides necessary capital for critical clinical trials, the high interest rate and the significant premium on the conversion price relative to the current market price introduce both opportunity and risk. The related-party nature of the transaction and the subordination of the debt warrant a cautious "hold" recommendation, awaiting further clarity on clinical trial progress and the company's overall financial performance before making a more definitive investment decision.

Keywords

CASI Pharmaceuticals, Convertible Note, Financing, SEC Filing, Schedule 13D, ETP Global III Fund, Biotechnology, Pharmaceuticals, Clinical Trials, CID-103, Debt Financing, Equity Conversion, Shareholder Ownership